CAPR · Capricor Therapeutics Inc.
AI read · Neutral
The AI's read
Capricor posted Q2 results and said its Deramiocel BLA remains under active FDA review, and the stock spiked ~67% after hours. That jump was met with heavy volume and a ~68% after-hours move, so price already reacted fast. The speed and size of the move reduce clear upside from here. High short interest and choppy small-cap biotech action mean this can easily retrace. Bottom line: we lean neutral. Wait for a concrete FDA update or sustained follow-through before shifting bias toward bullish.